Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Treasury Shares (2016 - 2025)

Cytokinetics (CYTK) has disclosed Treasury Shares for 14 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares changed N/A to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.6 million for FY2025, N/A changed from the prior year.
  • Treasury Shares for Q4 2025 was $2.6 million at Cytokinetics, up from $1.4 million in the prior quarter.
  • The five-year high for Treasury Shares was $2.6 million in Q4 2025, with the low at $1.2 million in Q4 2022.
  • Average Treasury Shares over 4 years is $1.6 million, with a median of $1.4 million recorded in 2021.
  • The sharpest move saw Treasury Shares grew 26.7% in 2021, then fell 14.18% in 2022.
  • Over 4 years, Treasury Shares stood at $1.4 million in 2021, then dropped by 14.18% to $1.2 million in 2022, then grew by 13.21% to $1.4 million in 2023, then skyrocketed by 87.27% to $2.6 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $2.6 million, $1.4 million, and $1.2 million for Q4 2025, Q4 2023, and Q4 2022 respectively.